// App-Quantinova.ai

1015 : Prognosis of triple negative breast cancer patients who attain pathological complete response with neoadjuvant carboplatin/docetaxel and do not receive adjuvant anthracycline chemotherapy.

Researchers

Presenter

  • Priyanka Sharma

Principal Investigators

  • Bruce F. Kimler

  • Claire Ward

  • Anne O'Dea

  • Marc Steven Hoffmann

  • Jennifer R. Klemp

  • Marilee McGinness

  • Jamie Lynn Wagner

  • Joshua Mammen

  • Amanda Leigh Amin

  • Carolyn Lehn

  • Roy A. Jensen

  • Andrew K. Godwin

  • Qamar J. Khan

Medical Centers

  • University of Kansas Medical Center, Westwood, KS

  • University of Kansas Medical Center, Westwood, KS

  • University of Kansas, Olathe, KS

  • University of Kansas Medical Center, Kansas City, MO

  • The University of Kansas Cancer Center, Kansas City, KS

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Triple-negative breast cancer

Biomarkers

  • N/A

Drug/Treatment

  • Carboplatin

  • Docetaxel

Outcome

  • N/A

Study Design

  • Prospective

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved